Stereology and immunohistochemistry of the myocardium in experimental hypertension: Long-term and low-dosage administration of inhibitor of the nitric oxide synthesis

Pathobiology

Volumn 67, Issue 1, 1999, Pages 26-33

  Gomes Pessanha, Mônica ^a,b   Mandarim de Lacerda, Carlos Alberto ^a   Dumas Hahn, Myriam ^b  

^a STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

Author keywords

Arterial hypertension; Collagen; Fibronectin; Myocardial hypertrophy; Myocardial remodeling; Nitric oxide

Indexed keywords

COLLAGEN TYPE 3; FIBRONECTIN; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; HEART MUSCLE; HEART VENTRICLE HYPERTROPHY; HYPERTENSION; IMMUNOHISTOCHEMISTRY; INTERSTITIUM; MUSCLE CELL; NONHUMAN; PRIORITY JOURNAL; RAT; STEREOLOGY; SYSTOLIC BLOOD PRESSURE;

ANIMALS; CELL COUNT; COLLAGEN; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; FIBRONECTINS; HYPERTENSION; IMMUNOHISTOCHEMISTRY; MYOCARDIUM; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; RATS; RATS, WISTAR; TIME FACTORS;

ANIMALIA;

EID: 6544290400     PISSN: 10152008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000028047     Document Type: Article

References (73)

1. Bayliss C, Mitruka B, Deng A: Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J Clin Invest 1992;90:278-281.
2. Ribeiro MO, Antunes E, Nucci G, Lovisolo SM, Zatz R: Chronic inhibition of nitric oxide synthesis: A new model of arterial hypertension. Hypertension 1992;20:298-303.
3. Klabunde RE, Ritger RC, Helgren MC: Cardiovascular actions of inhibitors of endothelium-derived relaxing factor (nitric oxide) formation/release in anesthetized dogs. Eur J Pharmacol 1991;199:51-59.
4. Weyrich AS, Ma XL, Buerke M, Murohara T, Rmstead VE, Lefer AM, Nicolas JM, Thomas AP, Lefer DJ, Vinten-Johansen J: Physiological concentrations of nitric oxide do not elicit an acute negative inotropic effect in unstimulated cardiac muscle. Circ Res 1994;75:692-700.
5. Kirstein M, Rivet-Bastide M, Hatem S, Bernadeai A, Mercadier JJ, Fischmeister R: Nitric oxide regulates the calcium current in isolated human atrial myocytes. J Clin Invest 1995;95: 794-802.
6. Arnal JF, Amrani EL, Chatellier G, Menard J, Michel JB: Cardiac weight in hypertension induced by nitric oxide synthase blockade. Hypertension 1993;22:380-387.
7. Morton JJ, Beattie EC, Speirs A, Gulliver F: Persistent hypertension following inhibition of nitric oxide formation in the young Wistar rat: Role of renin and vascular hypertrophy. J Hypertens 1993;11:1083-1088.
8. Bernátová I, Pechánová O: NO-deficient hypertension induced by L-NAME treatment in rats. J Mol Cell Cardiol 1994;26:123.
9. Thiedemann KU, Holubarsch C, Medugorac I, Jacob R: Connective tissue content and myocardial stiffness in pressure overload hypertrophy. A combined of morphologic, morphometric, biochemical and mechanical parameters. Basic Res Cardiol 1983;78:140-155.
10. Brilla GB, Pick R, Tan LB, Joseph SJ, Weber KT: Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 1990;67:1355-1364.
11. Boluyt MO, O'Neill L, Meredith AL, Bing OHL, Brooks WW, Conrad CH, Crow MT, Lakatta EG: Alterations in cardiac gene expressions during the transition from stable hypertrophy to heart failure: Marked upregulation of genes encoding extracellular matrix components. Circ Res 1994;75:23-32.
12. Brilla CG, Maisch B, Zhou G, Weber KT: Hormonal regulation of cardiac fibroblast function. Eur Heart J 1995;16(suppl C):45-50.
13. Weber KT, Janicki JS, Pick R, Capasso J, Anversa P: Myocardial fibrosis and pathologic hypertrophy in the rat with renovascular hypertension. Am J Cardiol 1990;65:1G-7G.
14. Tan LB, Jalil JE, Pick R, Janicki JS, Weber KT: Cardiac myocyte necrosis induced by angiotensin II. Circ Res 1991;69:1185-1195.
15. 1, fibronectin, and collagen. Circ Physiol 1992;31:H1861-H1866.
16. Anversa P, Kajstura J, Cheng W, Krzysztof R, Cigola E, Olivetti G: Insulin-like growth factor-1 and myocyte growth: The danger of a dogma. II. Induced myocardial growth: Pathologic hypertrophy. Cardiovasc Res 1996;32:484-495.
17. Okoshi MP, Matsubara LS, Franco M, Cicogna AC. Matsubara BB: Myocyte necrosis is the basis for fibrosis in renovascular hypertensive rats. Braz J Med Biol Res 1997;30:1135-1144.
18. Doering CW, Jalil JE, Janicki JS, Pick R, Aghili S, Abrahams G, Weber KT: Collagen network remodeling and diastolic stiffness of the rat left ventricle with pressure overload hypertrophy. Cardiovasc Res 1988;22:686-695.
19. Jalil JE, Doering CW, Janick JS, Pick R, Clarck WA, Weber KT: Structural vs contractile protein remodeling and myocardial stiffness in hypertrophied rat left ventricle. J Mol Cell Cardiol 1988;20:1179-1187.
20. Moreno H, Metze K, Bento AC, Antunes E, Zatz R, Nucci G: Chronic nitric oxide inhibition as a model of hypertensive heart muscle disease. Basic Res Cardiol 1996;91:248-255.
21. Moncada S, Higgs EA: Endogenous nitric oxide: Physiology, pathology and clinical relevance. Eur J Clin Invest 1991;21:361-374.
22. Nathan C: Nitric oxide as a secretory product of mammalian cells. FASEB J 1992;6:3051-3064.
23. G-Methyl-L-arginine, an inhibitor of L-arginine-derived nitric oxide synthesis, stimulates renal sympathetic nerve activity in vivo: A role for nitric oxide in central regulation of sympathetic tones? Circ Res 1992;70:607-611.
24. G-nitro-L-arginine methyl ester in conscious Brattleboro rats. Br J Pharmacol 1990;101:10-12.
25. Gardiner SM, Kemp PA, Bennett T, Palmer RMJ, Moncada S: Nitric oxide synthase inhibitors cause sustained, but reversible, hypertension and hindquater vasoconstriction in Brattleboro rats. Eur J Pharmacol 1992;213:449-451.
26. Numaguchi K, Egashira K, Takemoto M, Kadokami T, Shimokawa H, Sueishi K, Takeshita A: Chronic inhibition of nitric oxide synthesis causes coronary microvascular remodeling in rats. Hypertension 1995;26:957-962.
27. Palmer RMJ, Ferrige AG, Moncada S: Nitric oxide relase accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987;327:524-526.
28. Mandarim-de-Lacerda CA, Pereira EMM: Stereology of the myocardium in hypertensive rats under chronic inhibition of nitric oxide synthesis. Biomed Res 1997;8:153-160.
29. Pereira LMM, Mandarim-de-Lacerda CA: Estereologia do miocárdio em ratos hipertensos pelo uso de inibidor da síntese do óxido nítrico. Rev Port Cardiol 1997;16:753-758.
30. Pereira LMM, Vianna GMM, Mandarim-de-Lacerda CA: Stereology of the myocardium in hypertensive rats. Differences in relation to the time of inhibition of nitric oxide synthesis. Virchows Arch, in press.
31. Scherle W: A simple method for volumetry of organs in quantitative Stereology. Mikroskopic 1970;26:57-63.
32. Mattfeldt T, Møbius H-J, Mall G: Orthogonal triplet probes: An efficient method for unbiased estimation of length and surface of objects with unknown orientation in space. J Microsc 1985;139:279-289.
33. Weibel ER: Stereological Methods. Practical Methods for Biological Morphometry. London, Academic Press, 1979, vol 1.
34. Gundersen HJG, Bendtsen TJ, Korbo L, Marcussen N, MØller A, Nielsen K, Nyengaard JR, Pakkenberg G, SØrensen FB, Vesterby A, West MJ: Some new, simple and efficient stereological methods and their use in pathological research and diagnosis. APMIS 1988;96:379-394.
35. Mandarim-de-Lacerda CA: Stereology in the normal and pathological morphologic research. Biomed Res 1998;92:153-163.
36. Zar H: Biostatistical Analysis. Upper Saddle River, Prentice Hall, 1996.
37. Borg TK, Caulfield JB: The collagen matrix of the heart. Fed Proc 1981;40:2037-2041.
38. Weber KT: Cardiac interstitium: Extracellular space of the myocardium; in Fozzard HA (ed): The Heart and Cardiovascular System. New York, Raven Press, 1992, pp 1465-1480.
39. Cleutjens JPM: The role of matrix metalloproteinases in heart disease. Cardiovasc Res 1996; 32:816-821.
40. Ahumada GG, Saffitz JE: Fibronectin in rat heart. A link between cardiac myocytes and collagen. J Histochem Cytochem 1984;32:383-388.
41. Sládek T, Gerová M, Znojil V, Devát L: Morphometric characteristics of cardiac hypertrophy induced by long-term inhibition of NO synthase. Physiol Res 1996;45:335-338.
42. Meerson F: Contracile function of the heart in hyperfunctional hypertrophy and heart failure. Circ Res 1969:II/14:9-54.
43. Collins JF, Pawloki-Dahm C, Davis MG, Ball N, Dorn GW, Walsh RA: The role of the cytoskeleton in left ventricular pressure overload hypertrophy and failure. J Mol Cell Cardiol 1996;28:1435-1443.
44. Pereira LMM, Mandarim-de-Lacerda CA: Morfologia del miocardio en ratas sometidas a inhibicion cronica de la sintesis de oxido nitrico. Rev Chil Anat 1996;14:147-155.
45. Weber KT: Cardiac interstitium in health and disease: The fibrillar collagen network. J Am Coll Cardiol 1989;13:1637-1652.
46. Leonetti G, Cuspidi C: The heart and vascular changes in hypertension. J Hypertens 1995; 13(suppl 2):S29-S34.
47. del Monte F, O'Gara P, Poole-Wilson PA, Yacoub M, Harding SE: Cell geometry and contractile abnormalities of myocytes from failing human left ventricle. Cardiovasc Res 1995;30: 281-290.
48. Hess OM, Villari B, Krayunbuehl HP: Diastolic dysfunction in aortic stenosis. Circulation 1993;87:IV73-IV76.
49. Grossman W: Cardiac hypertrophy: Useful adaptation or pathologic process? Am J Med 1980;69:576-583.
50. Kannel WB: Implications of Framingham study data for treatment of hypertension: Impact of other risk factors; in Laragh JH, Buhler FR, Seldin SW (eds): Frontiers in Hypertension Research. New York, Springer, 1981, pp 17-21.
51. Pfeffer JM, Pfeffer MA, Mirsky I, Braunwald E: Regression of left ventricular dysfunction by captopril in the spontaneously hypertensive rat. Proc Natl Acad Sci USA 1982;79:3310-3314.
52. Gavras H: Hypertension and congestive heart failure: Benefits of converting enzyme inhibition (captopril). J Am Coll Cardiol 1983;1: 518-520.
53. Medugorac I: Collagen content in different areas of normal and hypertrophied rat myocardium. Cardiovasc Res 1980;14:551-554.
54. Weber KT, Clark WA, Janicki JS, Shroff SG: Physiological versus pathologic hypertrophy and the pressure overloaded myocardium. J Cardiovasc Pharmacol 1987;10:537-550.
55. Omens JH, Milkes DE, Covell JW: Effects of pressure overload on the passive mechanics of the rat left ventricle. Ann Biomed Eng 1995;23: 152-163.
56. Silver MA, Pick R, Brilla CG, Jalil JE, Janicki JS, Weber KT: Reactive and reparative fibrillar collagen remodelling in the hypertrophied rat left ventricle: Two experimental models of myocardial fibrosis. Cardiovasc Res 1990;24: 741-747.
57. Willems IEMG, Arends J-W, Daemen MJAP: Tenascin and fibronectin expression in healing human myocardial scars. J Pathol 1996;179: 321-325.
58. Casscells W, Kimura H, Sanchez JA, Ferrans VJ: Immunohistochemical study of fibronectin in experimental myocardial infarction. Am J Pathol 1990;137:801-810.
59. Knowlton AA, Connelly CM, Romo GG, Mamuya W, Apstein CS, Brecher P: Rapid expression of fibronectin in the rabbit heart after myocardial infarction with and without reperfusion. J Clin Invest 1992;89:1060-1068.
60. Shekhonin BV, Domogatsky SP, Idelson GL, Koteliansky VE: Participance of fibronectin and various collagen types in the formation of fibrous extracellular matrix in cardiosclerosis. J Mol Cell Cardiol 1988;20:501-508.
61. Nogami K, Kusachi S, Niiya K, Moritani H, Tsuji T: Changes in extracellular matrix components in cardiomyopathic Syrian hamster, BIO 14.6. Jpn Circ J 1995;59:631-640.
62. Ratajska A, Campbell SE: Fibronectin accumulation within cardiac myocytes in rats with elevated plasma angiotensin II. Cardiovasc Pathol 1995;4:57-67.
63. Leslie KO, Taatjes DJ, Schwarz J, von Turkovich M, Low RB: Cardiac myofibroblasts express alpha smooth muscle actin during right ventricular pressure overload in the rabbit. Am J Pathol 1991;139:207-216.
64. Bernátová I, Pechanová O, Simko F: Captopril prevents NO-deficient hypertension and left ventricular hypertrophy without affecting nitric oxide synthase activity in rats. Physiol Res 1996;45:311-316.
65. Weber KT, Janicki JS, Shroff SG, Pick R, Chen RM, Bashey RL: Collagen remodeling of the pressure-overloaded, hypertrophied nonhuman primate myocardium. Circ Res 1988;62: 757-765.
66. Alpert NR, Hamrell RB, Halpern W: Mechanical and biochemical correlates of cardiac hypertrophy. Circ Res 1974;34:71-82.
67. Medugorac I, Jacob R: Characterization of left ventricular collagen in the rat. Cardiovasc Res 1983;17:15-21.
68. Weber KT, Brilla CG: Pathologic hypertrophy and cardiac interstitium. Circulation 1991;83: 1849-1865.
69. Speranza ML, Valentini G, Calligaro A: Influence of fibronectin on the fibrillogenesis of type I and type III collagen. Coll Relat Res 1987;7:115-123.
70. Vivaldi MT, Eyre DR, Kloner RA, Schoen FJ: Effects of methylprednisolone on collagen biosynthesis in healing acute myocardial infaretion. Am J Cardiol 1987;60:424-425.
71. Whittaker P, Boughner DR, Kloncr RA: Analysis of healing after myocardial infarction using polarized light microscopy. Am J Pathol 1989; 134:879-893.
72. Regan CP, Anderson PG, Bishop SP, Berecek KHC: Captopril prevents vascular and fibrotic changes but not cardiac hypertrophy in aorticbanded rats. Am J Physiol 1996;271:H906-H913.
73. Läthteenmäki TA, Sievi E, Vappatalo H: Antihypertensive drugs reduce noradrenaline-induced hypertrophy of cultured myocardial cells. J Pharm Pharmacol 1996;48:323-326.